Boehringer Will Test How Pradaxa Stacks Up To The Competition In Real-World Study

Global observational study is assessing real-world experience with Pradaxa and other anticoagulants in patients with newly diagnosed atrial fibrillation who are at risk of stroke. Results are due in 2020.